Completed × NIH × Lymphoma, Large-Cell, Anaplastic × Clear all Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
348 enrolled 15 charts
Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
Phase 2 Completed
137 enrolled 13 charts
T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
Phase 1 Completed
26 enrolled 19 charts
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies
Phase 1 Completed
8 enrolled 18 charts
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Phase 2 Completed
60 enrolled 8 charts
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 2 Completed
93 enrolled 12 charts
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
Phase 1/2 Completed
43 enrolled 18 charts
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma
Phase 1 Completed
34 enrolled
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
Phase 1 Completed
17 enrolled
Phase I Study of HeFi-1 to Treat Cancers With CD30 Protein
Phase 1 Completed
9 enrolled
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma
Phase 2 Completed
42 enrolled 10 charts
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
14 enrolled 7 charts
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
Phase 1 Completed
80 enrolled
UCN-01 and Prednisone in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
24 enrolled
Flavopiridol in Treating Patients With Refractory Cancer
Phase 1 Completed
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
Phase 1 Completed
30 enrolled
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
Phase 2 Completed
22 enrolled 5 charts
Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Phase 2 Completed
51 enrolled 14 charts
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Phase 1 Completed
45 enrolled
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy
Phase 1 Completed
42 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction
Phase 1 Completed
15 enrolled
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma
Phase 1 Completed
57 enrolled
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
12 enrolled
Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 2 Completed
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma
Phase 3 Completed
VNP40101M in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
Phase 1 Completed
AMG-479 in Treating Patients With Advanced Solid Tumors or Non-Hodgkin Lymphoma
Phase 1 Completed
64 enrolled
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma
Phase 1 Completed
20 enrolled
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
Phase 1 Completed
Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer
Phase 2 Completed
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
Phase 2 Completed
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma
Phase 1/2 Completed
BCX-1777 in Treating Patients With Refractory Cancer
Phase 1 Completed
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
Phase 1 Completed
28 enrolled
Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma
Phase 1 Completed
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
Phase 1 Completed
55 enrolled
Combination Chemotherapy in Treating Patients With Advanced Cancer
Phase 1 Completed
25 enrolled
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer
Phase 1/2 Completed
30 enrolled
Donor Stem Cell Transplant After Conditioning Therapy in Treating Patients With Hematologic Cancer, Recurrent or Metastatic Solid Tumor, or Other Disease
Phase NA Completed
30 enrolled
Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis
Phase 1 Completed
Decitabine in Treating Patients With Melanoma or Other Advanced Cancer
Phase 1 Completed
Perillyl Alcohol in Treating Patients With Refractory Cancer
Phase 1 Completed
25 enrolled
Penclomedine in Treating Patients With Solid Tumors or Lymphoma
Phase 1 Completed
30 enrolled
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Phase 1 Completed
40 enrolled
BMS-247550 in Treating Patients With Advanced Cancers
Phase 1 Completed
54 enrolled
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
Phase 1 Completed
60 enrolled
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction
Phase 1 Completed
60 enrolled